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Abstract The ELISpot assay is used for the detec-
tion of T cell responses in clinical trials and vaccine
evaluations. Standardization and reproducibility are
necessary to compare the results worldwide, inter- and
intra-assay variability being critical factors. To assure
operator safety as well as high-quality experiment
performance, the ELISpot assay was implemented on
an automated liquid handling platform, a Tecan
Freedom EVO. After validation of the liquid handling,
automated loading of plates with cells and reagents
was investigated. With step by step implementation of
the manual procedure and liquid dispensing
optimization on the robot platform, a fully automated
ELISpot assay was accomplished with plates remain-
ing in the system from the plate blocking step to spot
development. The mean delta difference amounted to
a maximum of 6%, and the mean dispersion was
smaller than in the manual assay. Taken together, we
achieved with this system not only a lower personnel
attendance but also higher throughput and a more
precise and parallelized analysis. This platform has the
potential to guarantee validated, safe, fast, repro-
ducible and cost-efficient immunological and toxico-
logical assays in the future.
Keywords ELISpot  Automation  Liquid classes 
Operator safety  HIV vaccines  PBMC
Introduction
Developed first in 1983 to detect antibody secreting
cells (Czerkinsky et al. 1983), the enzyme linked
Immunospot (ELISpot) assay improved continually
and gained more and more attention over the years
(Czerkinsky et al. 1988). With the recommendation of
the 13th International AIDS Congress in 2000 to use
the ELISpot technique due to its performance for
immunomonitoring purposes, it became one of the
most important ex vivo methods in cellular immunol-
ogy (Janetzki 2004). Based on the ELISA technique,
the ELISpot assay is used worldwide in diverse areas
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ranging from vaccinology and tumorology to infec-
tious diseases and transplantation (Almeida et al.
2009). Besides the detection, measurement and char-
acterization of immune cell activities in clinical and
cancer trials (Cox et al. 2006), it helps to evaluate new
vaccines in order to control and prevent infectious
diseases such as those caused by mycobacterium
tuberculosis (Bathoorn et al. 2011; Kobashi et al.
2010), hepatitis-C-virus and HIV (Lee et al. 1989).
Despite this potential, inter-operator and inter-
assay inconsistency of the measurement is one of the
most critical limitations of the method (Janetzki
2004). As clinical trials require comparability and
reproducibility of results, the ELISpot assay therefore
should be more simple and accurate to become a
standardized and validated method. The first steps to
harmonize the process for industrial applications
included standardization of protocols, materials and
reagents e.g. by using pre-coated 96 well plates (Cox
et al. 2006) and well-defined antibodies and enzymes
(Janetzki 2004). As shown by the Cancer Vaccine
Consortium (CVC), protocol choices and laboratory
practices can have dramatic effects on assay perfor-
mance (Janetzki et al. 2008). The CVC described in a
guideline the recommendations for successful assay
outcome such as established laboratory standard
operation procedures (SOP), counting method, cell
preparation, serum quality and spot evaluation. These
conditions result from two ELISpot proficiency panels
initiated in 2005 which were aimed to identify
deficient practices and common sources of variability
between laboratories to increase standardization
(Janetzki et al. 2008). One complementary approach
to improve the assay was the introduction of automa-
tion along the process as described in Janetzki et al.
(2004). Two automated machines had particularly
great impact on the standardization and simplification
of the ELISpot assay. First, the introduction of
automated cell counters on the market permitted
comparable viable starting cell concentrations in all
laboratories without individual cell counting and
method variability. Second, the implementation of
automated ELISpot readers (Hawkins et al. 2006;
Zadorozhny and Martynov 2012) allowed the evalu-
ation of assay results by counting developed spots
automatically. This option offers a rapid and compli-
ant assessment with lower variability than manual spot
counting on a stereomicroscope. Despite this progress
of automation, the ELISpot assay is still a very error-
prone method depending on many parameters like cell
cryopreservation (Maecker et al. 2005), reagent man-
ufacturer, incubation times, spot evaluation (Janetzki
et al. 2004), analysis criteria (Janetzki 2004; Moodie
et al. 2012) and operator pipetting accuracy (Almeida
et al. 2009; Maecker et al. 2008).
Our challenge in this study was to reduce these
detrimental influences by developing an automated
ELISpot assay. The aim was to minimize the human
factor on inter-operator, inter-assay and intra-assay
variability and optimize precision and reproducibility
(Janetzki et al. 2008). An automated system that
employs robotic technology to control processes or to
achieve automatic operations without human inter-
vention has many advantages. It allows high repro-
ducibility and result accuracy combined with a high
throughput of data through parallelization and
scheduling, a continuous and safe electronic control
of the process with data recording, a non-stop working
time and above all, cost-efficiency with a low need of
personnel. All these performance indicators increased
the interest in automated platform development in the
last decade (Ferreira et al. 2011; Jiang et al. 2012;
Leguia et al. 2011; Sarkozi et al. 2003) and fulfilled
many expectations of the pharmaceutical industry in
search of GCLP-validated high throughput screening
systems. Various platforms have recently been devel-
oped to be used as closed and sterile systems,
integrating all necessary biological devices for cell
culture and maintenance (Koike et al. 2012; McLaren
et al. 2013) or pseudovirus production (Schultz et al.
2012). First tests of an automated ELISpot assay have
been performed with a simple liquid handling robot
combined with a cell counter, as well as a plate washer
and reader by Almeida et al. (2009). The system
described by us here allows, in addition, the complete
integration and automation of cell culture and incu-
bation steps, so that plates remain in the system from
the plate blocking step to spot development.
Based on our expertise in implementing and
validating an automated system under GCLP, we (1)
show a technical way to improve an automated
immunomonitoring tool on a pipette robot platform
and (2) define which parameters have to be considered,
characterized and adapted. In this paper we focus on
the automation of the ELISpot assay due to the
infectious potential of the assay and the necessity to
reduce the risk for the personnel. At the end of the
process optimization we demonstrate the feasibility of
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running a safe assay and obtain precise results, in a
short time. This assembly of several automated steps
in a higher process minimizes dangerous contacts of
the laboratory staff with infectious cell samples by
realizing the process in a closed, safe and sterile
environment. At the same time, a higher sample
number can be tested with better accuracy and lower
personnel attendance. This setup is suitable for labo-
ratories in which highly pathogenic microbes are
handled and operator protection has to be guaranteed.
In addition, the platform could be used for a central-
ized evaluation of large vaccination multicenter
studies to avoid laboratory and operator dependency
and to provide the highest possible results
comparability.
Material and method
Blood cells isolation and cryopreservation
Citrated buffy coats were provided by the blood donor
center ‘‘Blutspendezentrale Saar-Pfalz gGmbH Am
Klinikum Saarbru¨cken’’ in Saarbru¨cken (URL: http://
www.blutspendezentrale-saarpfalz.de/index.html) with
written informed consent of the donors (for research
purposes). According to German national regulations,
blood donor centers do not necessitate specific ethics
statement for blood collections (Germann et al. 2013).
The lymphocytes were separated from the erythrocytes
with the Ficoll solution LSM 1077 (PAA, Co¨lbe, Ger-
many). After a first centrifugation step (2000 rpm,
30 min, without brake) the peripheral blood mononu-
clear cells (PBMC) interphase layer was collected and
washed once with phosphate-buffered saline solution
(PBS) (Gibco, Darmstadt, Germany). After measure-
ment of cell concentration and viability on the auto-
mated cell analyzer Vi-Cell XR (Beckman Coulter,
Krefeld, Germany), PBMCswere resuspended in 10 ml
R10 medium with a concentration of 1 9 106 cells/ml
and cultured overnight (37 C, 5% CO2) for direct use
in the ELISpot assay. R10medium contains RPMI 1640
(Gibco, Darmstadt, Germany), 10% fetal bovine serum
(FBS) (PAA, Co¨lbe, Germany), 1% Glutamax (Invit-
rogen, Darmstadt, Germany), 1% Penicillin/Strepto-
mycin (PAA, Co¨lbe, Germany) and 2.5% 1 M HEPES
(Gibco, Darmstadt, Germany). Alternatively, 1 9 107
cells/ml PBMCs were frozen with serum-free GHRC
cryomedium (Schulz et al. 2012) for subsequent
experiments and thawed one day before the ELISpot
plate loading. Cryovials were held in 37 C water bath
until a small ice crystal remained. Then 1 ml warmR10
medium was slowly added to the vial and the thawed
cell suspension was directly transferred into 8 ml R10
medium. To avoid toxic effects of dimethylsulfoxid
(DMSO) still present in the cell suspension, PBMCs
were centrifuged for 10 min with 400 g and the pellet
was re-suspended in 10 ml R10 medium. Cells rest
overnight in the incubator at 37 C and 5% CO2.
ELISpot assay
Figure 1 illustrates the step by step workflow of an
ELISpot assay from cell thawing to substrate devel-
opment, as described here. The ELISpot assay requires
an antibody-coated 96 well plate (anti-IFN-gamma
mAb 1 D1k pre-coated, Mabtech, Nacka Strand,
Sweden), prewashed with PBS (Gibco, Darmstadt,
Germany) and blocked with R10 medium. After at
least 30 min blocking time, 50 ll of a specific CEF
(cytomegalovirus, Epstein–Barr virus, influenza virus)
peptide pool, CMV (cytomegalovirus) peptide pool
and PHA (phytohemagglutinin), respectively, were
added per well. The samples were run in triplicates.
R10 medium was used as negative control. The final
stimulant concentration per well was 2 lg/ml for the
CEF Peptide Pool (CTL, Bonn, Germany), 1 lg/ml for
CMV (PepMix HCMVA pp65, JPT, Berlin, Germany)
and 4 lg/ml for the lectin PHA (Sigma, Taufkirchen,
Germany). 50 ll cell suspension with a concentration
of 2 9 106 cells/ml was added to each well with wide
bore tips (MBP 200G, VWR, Darmstadt, Germany).
After loading, the plate was stored for 20–24 h in the
incubator at 37 C and 5% CO2 and agitation was
avoided to enable binding of secreted cytokines to the
coated membrane.
On the next day, 50 ll/well detector antibody
solution was added after a PBS washing step for
cytokine detection. The solution consisted of a 1:200
dilution of antibody (anti-human IFN-gamma Detec-
tor antibody 7B6-1 HRP conjugated, Mabtech, Nacka
Strand, Sweden) in sterile and filtered PBS containing
0.5% FBS. After 2 h of incubation time, unbound
antibodies were removed by an automated washer
(HydroFlex, Tecan, Crailsheim, Germany) and 50 ll/
well substrate (Nova Red, Biozol, Eching, Germany)
were incubated for 5 min. The reaction was stopped
and the plate was dried overnight. Each developed
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spot corresponded to a cytokine producing-cell. The
plate was finally scanned and automatically evaluated
using an ELISpot Analyser from CTL (Bonn,
Germany) and its ImmunoScan and ImmunoSpot
software. Different parameters (Dittrich and Lehmann
2012) were configured such as the spot separation (set
to 0), the minimal manual gating (set to 0.0041 mm2)
and the counted area (set to 95%). Results were
represented in graphs with the donors and antigens as
x-axis and the amount of spot (Spot Forming Cells
SFC/106 PBMCs) as y-axis.
Determination of delta difference, coefficient
of variation and dispersion
For the comparison of manual and automated pipetting
during the gravimetrical analysis, we computed with
n = 48 for the fixed tips and n = 24 for the disposable
tips:
• the coefficient of variation (CVpipetting) to analyze
the precision and repeatability of the conducted
experiment, according to:
CVpipetting ¼ SDX  100 ð1Þ
with SD for standard deviation and X for the mean
volume
• the delta difference (Dpipetting) to evaluate the
accuracy of the liquid distribution, according to:











where XðsetÞ represents the required pipetting
volume and XðmeasuredÞ the actual detected.
In consequence, the CV represents the extent of
variability in relation to the mean volume, while the
delta difference describes the dispersion of the results
in comparison to the reference value.
To implement the automated ELISpot assay, we
determined different parameters to evaluate the spot
forming cells (SFC) on developed assays:
• the coefficient of variation (CVspot) to evaluate the





with SD for standard deviation and X for the spot
count with n = 71 delta difference values for the
pipetting accuracy test (W-Form). These values
Fig. 1 Workflow of the ELISpot assay steps over 4 days from
cell preparation to plate analysis
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are based on the 12 PHA and CEF spot counts of
three plates minus one outlier.
• the delta difference (Dspot and D) to evaluate the
accuracy of the automated spot counts, according
to:
Dspot ¼ XðautomatedÞ  XðmanualÞ
XðmanualÞ  100 ð4Þ
where XðautomatedÞ represents the spot count of
the automated assay and XðmanualÞ the spot count
of the manual assay with n = 71 values during the













where XðautomatedÞ represents the mean of the
automated values and XðmanualÞ refers to the
mean manual ones, respectively. During the com-
parison of the automated and manual assays, each
sample was measured in triplicates with n = 3 for
the conducted Tests 1, 2, 3 and 4.
• the variance (Var) and dispersion (Dis) to show the






ðSFCi  XÞ2 ð6Þ





ðSFCi  XÞ2 ð7Þ
where SFCi represents the spot count and X refers
to the mean value with n = 3 for the conducted
Tests 1, 2, 3 and 4.
Test 1 to Test 4 compared manual and automated
assays, based on the parameters D and Dis. The D
value represents the relative change between the
manual and the automated assay, while the dispersion
refers to the spreading or distribution of the samples.
The smaller these values are, the more similar are both
assays.
To compare the manual process with the automated
one, the Wilcoxon signed-rank test was additionally
used. In this case, each well measurement was
considered as a single value with p[ 0.05 as a
significance limit. Values with the CEF peptide pool
and the CMV peptide pool were calculated separately,
resulting in n = 12 (Test 1–Test 4).
Pipette robot assembly
The liquid-handling robot platform Tecan Freedom
EVO 200 consisted of different cell culture modules
(Fig. 2). The liquid-handling arm (LiHa) with 4 fixed
steel needles and 4 needles with single-use tips allows
liquid level detection through conductivity (Fig. 2b).
The robotic manipulator arm (RoMa) with gripper
enables labware transfer between the different devices
(Fig. 2c). A refrigerator (Revco, Waltham, MA, USA)
is used for the storage of highly purified water as
system liquid (Water For InjectionWFI, Lonza, Basel,
Switzerland). Additionally, the platform contains a
worktable of 2 m length, pumps for precise liquid
transfer, a dark chamber (TIG, Tecan, Crailsheim,
Germany) for sample incubation and a sterile laminar
flow cabinet over the platform. The cell culture
incubator (37 C and 5% CO2, StoreX500, Liconic,
Mauren, Liechtenstein) and a Carousel (CarouselNT,
Liconic, Mauren, Liechtenstein) for plate supply are
directly coupled with the worktable by a transfer
station.
The devices follow the guidelines of the American
National Standards Institute (ANSI) and the Society
for Laboratory Automation and Screening (SLAS)
which recommend automation standards (Meets the
Standards ANSI/SLAS 1-2004 through ANSI/SLAS
4-2004 2004). The pipetting volume per needle was
limited by 1 ml syringe capacity and could be
dispensed with three different possible modes. They
were called Free dispense, Wet Contact and Dry
Contact. The first one, mostly relevant, occurred in the
air while the two other modes took place in contact
with liquid and labware, respectively.
The system was controlled by the Tecan software
EVOware Standard. The configuration of the work-
table, the carriers and labwares were integrated in the
software interface to program processes. Each device
was configured in accordance with the characteristics
given by the manufacturers. For example, the pre-
coated 96 well plate (Mabtech, Nacka Strand, Swe-
den) has the following specifications: a membrane
area of 0.26 cm2 and plate dimensions of
127.8 mm 9 85.5 mm 9 14.4 mm (L 9 W 9 D).
The program also requires information for both arms,
such as the dispense height (1 cm above the mem-
brane), the lowest aspirate position (z-max) without
touching the membrane (B1 mm gap) or the transfer
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vector between two devices as references. The system
was configured to reach 1/10 mm motion and 1–1/
10 ll volume accuracy, depending on the tip capacity.
The aspirate and dispense commands were defined in
‘‘liquid classes’’, where flow speed (in ll/s) and air gap
(in ll) parameters influence the correct and accurate
treatment of the liquid, based on its conductivity and
viscosity.
Fig. 2 Automated pipetting platform Tecan Freedom EVO.
a Whole system with incubator, carousel, cell counter and
laminar flow amongst other devices. b LiHa (Liquid Handling
Arm) including the four fixed needles and the four needles with
single-use tips. c RoMA (Robot Manipulator Arm). Cell culture
devices are numbered: (1) Refrigerator, (2) Incubator, (3) LiHa,
(4) RoMa, (5) Wash station, (6) Dark room incubator, (7)
Carousel
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Results
Initial preprocessing configuration and validation
of the automated procedure
Gravimetrical analysis
An important requirement of an automated, repro-
ducible ELISpot-system is the accuracy and precision
guaranteed by the tips used for liquid distribution. To
determine the appropriate pipette form, we compared
in a gravimetrical analysis two different pipetting
systems. The results showed that fixed tips enable in
general more accurate and reproducible liquid han-
dling with for example -1.029% accuracy against
-1.598% for the disposable tips in a 100 ll volume
range (Table 1). Due to this results and the plate
design, fixed tips were used for cell handling with the
Free dispense mode and the multichannel and multi-
pipette options resulting in fast, reproducible and
contactless suspension transfer. Despite the higher
dispersion, the disposable tips were suitable with
accuracy under 10% in a 10 ll range. Additionally,
they showed a better precision of the liquid distribu-
tion in this volume range due to smaller tip capacity
(200 ll) instead of 1000 ll for the fixed tips. Accord-
ing to this and especially in order to avoid peptide
carryover and time-consuming washing steps in
between, the disposable tips were used for the
distribution of the three peptide mixes and the control
reagent as T cell stimuli for cytokine secretion. It was
most important to load the plate with minimal delay to
limit the intra-assay variability. With this combina-
tion, the automated procedure for plate loading was
faster (3 min processing time) compared to the manual
procedure (10 min), in which wide bore tips are used
for the cells only once per well.
In addition, selection and adaptation of specific
liquid classes were also relevant for the pipetting
accuracy. These liquid classes are liquid-dependent,
based on conductivity and viscosity characteristics.
They consist of a set of parameters such as flow speed
and air gap conditions, influencing accurate and
precise pipetting liquids. In previous tests (unpub-
lished work) liquid handling parameters were opti-
mized with respect to homogenous microcarrier
distribution over a 96 well plate (75% of the wells
had an aberration lower than 20%). Based on these
experiments, 600 ll cell suspension were mixed 3
times with a moderate dispense flow rate (400 ll/s) at
the bottom of the cell container using 1000 ll fixed
needles. The inner diameter of the fixed needles
(0.5 mm) was smaller than the inner diameter of the
1000 ll disposable tips (0.8 mm). To avoid nonspeci-
fic immunological activity induced by shear forces, the
donor cells had in effect to be treated carefully and
were aspirated with a low flow rate (100 ll/s) for the
plate loading. In comparison to the cells, reagents were
aspirated with a standard flow rate of 150 ll/s and
dispensed with 600 ll/s in plate. A high breakoff
speed (400 ll/s) guaranteed blow out of the complete
liquid volume, without residues on the tip end.
Determination of the tips accuracy
To confirm the accuracy of the automated pipetting,
three donors were tested with each on one half of a
plate with the CMV peptide pool and PHA pipetted in
W-form over 4 rows (Fig. 3). This test adapted from
Almeida et al. (2009) demonstrated the reproducibility
of the automated cell adding pipetting step within a
plate, medium was used as background negative
control. Within general\20% variation, no relation
between wells and locations on plate were detected.
Values, which were lower than 25% of the mean, were
not considered in the calculation. Only one (Second
donor with PHA combination in the automated assay)
of seventy-two measurements was excluded based on
Table 1 Gravimetrical analysis of the Tecan Freedom EVO 200
Tips Pipetted volume (ll) Mean (ll) Dpipetting (%) CVpipetting (%)
1000 ll Fixed tips (49) (n = 48) 100 98.971 -1.029 0.320
10 10.367 3.671 2.307
200 ll Disposable tips (29) (n = 24) 100 98.402 -1.598 0.585
10 9.152 -8.483 1.819
Twelve dispensing actions of four fixed tips and two disposable tips are measured with 10 and 100 ll volume on scales. Shown are
the pipetting accuracy (Dpipetting) and coefficient of variation (CVpipetting) of the system for different pipetted volumes
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this criteria. The mean CVspot was 11.7% for the
manual and 15.9% for the automated assays. Themean
Dspot over the three plates between both pipetting
modes indicated a difference of -5.9% for the
automated results, which is acceptable.
First comparison of the manual and automated
procedures (test of the plate loading)
After gravimetrical analysis and pipetting accuracy
test (W-Form), we started the comparison of the
manual and automated processes. In the first step we
focused on the homogenous and reproducible plate
loading with reagents and cells referring to Test 1. We
compared this manually or automatically performed
step on four donors in a separate analysis, the rest of
the assay was done manually. In the medium-contain-
ing part of the automated plate (negative control) no
carryover was observed with maximum 1 spot per
well. This result confirmed the correct utilization of
the Free dispense mode (no liquid in well touched
during distribution). To be able to compare both
assays, D and Dis were observed, respectively, as
parameter for the relative difference to the manual
value and as parameter for range/spreading between
both assays. Each sample was measured in triplicates
(n = 3). The smaller the D and Dis values were, the
more precise and comparable were the manual and
automated assays. The results of this initial experiment
(Table 2, Test 1) show a high spread between the
manual and the automated plates with a D range
between 3.7 and 54.5%. For the donor with the highest
value (54.5%, donor 1), Dis of the manual assay
reached 0.6 and, respectively, 0.4 for the automated
assay. In comparison, the donor with the lowest D
value (3.7%, donor 4) reached a Dis value of 11.5
(manual) and 23.7 (automated). Even in the first step
with discrepancy in manual and automated values, a
well to well analysis (n = 12) with the Wilcoxon
signed-rank test resulted in a p value [0.05 and
showed no significant difference between both assays.
Optimization and enhancement of the automated
procedure
Technical implementation of the automated process
In order to improve process automation, different
parameters were primarily adapted from Test 1: cells
were mixed only two times and the delay after aspirate
action was raised to 300 ms in order to balance the
under-pressure in the tips and thereby rest the cells.
Fig. 3 Pipetting scheme of the inter-plate reproducibility test
for manual and automated cell adding. The test is performed
with manual (upper part) and automated (under part) cell
adding over one half plate and investigates the relation between
wells and locations on plate. The wells on the scheme represent
the repartition of the manual pipetted PHA (dark gray), CMV
(bright gray) and Medium (white)
64 Cytotechnology (2017) 69:57–73
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In the following step (Test 2) the automated
washing steps and antibody dispense were added to
the previous reagent and cell loading. Additionally,
different parameters were adapted and improved for
Test 2 based on the experience in Test 1. PBS aspirate
and dispense speeds were, respectively, set to 100 and
200 ll/s instead of 150 and 600 ll/s to avoid long-
term damage of the plate membrane. A random liquid
increase in the testing plate was observed after
repeated washing steps. To counteract this effect,
two remedial actions were established. First, the
aspirated volume during washing steps was increased
from 200 to 230 ll in order to avoid surplus volume.
Second, the lowest aspiration position, determined by
the constant z-max, guaranteed comparable start
volumes in the well for the antibody dispensing step.
In accordance with the manual operating procedure,
the plate was washed five times with PBS after
overnight incubation as well as after antibody incu-
bation. PBS also had to be removed as thoroughly as
possible without touching the membrane to avoid
dilution of the antibody solution. Normally, any
remaining solution is flicked manually onto a paper
towel. In the automated process, the way to aspirate
liquid during washing steps was changed. We decided
not to aspirate the solution from the middle of the well
as usual but 2 mm away from the edge. Since liquids
build a concave surface due to the protein-binding
properties of the plate membrane, more liquid can be
removed from the same aspirate height (as shown in
Fig. 4). This minimizes the residual volume first
estimated as not significant for the following test.
In experiment ‘‘Test 2’’, the results of three
combined automated workflow steps (reagent and cell
loading, washing steps as well as antibody loading and
incubation) were compared to the manual assay. Four
donors were tested, one CEF-negative and CMV low-
responder (donor 5), one CMV-negative and CEF low-
responder (donor 6) and two donors (donor 7 and 8)
with an immunological reactivity ranging between
2000 and 7000 SFCs/106 PBMCs. Samples were still
run and evaluated as triplicates except donor 8 for CEF
reagent, that was evaluated as duplicate due to an
outliner. Samples of both negative donors (donors 5
and 6) together with the medium-containing wells
showed as expected a low background signal with
maximum 3 spots per well. To enable a representative
analysis of the further tests, we evaluated only the
results of donors 7 and 8 as high and middle
responders (Table 3, Test 2). Samples from these
remaining donors showed a D range of 4.2 to 12.1%
between the automated ELISpot assay and the man-
ually-performed assay. The changes between Test 1
and Test 2 enhanced a decrease of the maximalD value
of over 75% (54.5–12.1%). The results showed also an
amelioration of the Disautomated with a maximal value
of 7.5 compared to the manual value of 15.2 and the
maximal automated value of Test 1 with 25.6. The
Wilcoxon signed-rank test (n = 12) revealed with a
p value [0.05 that the automated assay was not
significantly different than the manual assay.
Reagent adaptation based on automation
requirements
To further improve the automated process, we intro-
duced for Test 3 inner and outer ethanol incubations of
the fixed tips before and after experiments improving
Table 2 Statistics of the manual and automated ELISpot assays for Test 1 and donor 1 to donor 4
Assay Donor Peptide D (%) DisManual DisAutomated
Test 1 (Cells and reagents loading) 1 CEF 54.5 0.6 0.4
1 CMV 10.0 9.2 8.9
2 CEF 14.3 3.8 9.0
2 CMV 37.5 0.2 7.5
3 CEF 11.8 5.1 25.6
3 CMV CMV(–) – –
4 CEF 16.4 10.9 0.7
4 CMV 3.7 11.5 23.7
For each donors (1–4) and the peptide CEF and CMV, D and Dis (manual and automated) were evaluated for Test 1. The D value is
representative as accuracy measurement for the relative difference between the manual and automated spot count mean. Dis is
referring as a spot distribution statement
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the precision of the volume dispensing and minimiz-
ing the adhesion of residual liquid at the tips.
Furthermore, owing to the displaced aspirate position
during the PBS washing steps, a reduction of residual
liquid volume by almost 50% with 14.4 ± 3 ll
instead of 28.4 ± 3 ll per well was achieved. Calcu-
lated from a safe gap of minimum 0.45 mm between
the membrane surface and z-max height of the tip, a
residual volume of 13 ll is necessarily remaining in
the well. However, this undesired liquid can dilute the
antibody solution. To compensate this, the antibody
concentration of the automated assays was increased
(around 1:155 instead of 1:200 stock dilution) with the
final volume remaining at 50 ll per well. The
Fig. 4 Volume removal from a well with two different
approaches. In both cases, the liquid forms a concave level
due to membrane properties. a fixed tip (1) is positioned in the
middle of the well and aspiration is limited by z-max over the
whole well length. b the tip removes the maximum volume (2)
on the edge of the well without touching the membrane (3)
Table 3 Statistics of the manual and automated ELISpot assays for Test 2 to Test 4 and donor 7 to donor 8
Assay Donor Peptide D (%) DisManual DisAutomated
Test 2 (Addition of washing steps and antibody loading) 7 CEF 6.6 6.0 7.5
7 CMV 12.1 1.2 1.7
8 CEF 7.5a 5.6 0.1a
8 CMV 4.2 15.2 3.2
Test 3 (Compensation of the antibody concentration) 7 CEF 4.5 0.9 8.7
7 CMV 4.5 5.8 0.7
8 CEF 13.9 0.4 18.7
8 CMV 6.3 1.4 0.4
Test 4 (Addition of the blocking and substrat development steps) 7 CEF 5.8 11.5 1.4
7 CMV 3.7 12.2 0.7
8 CEF 6.1 3.3 11.1
8 CMV 0.7 1.3 4.2
For each donor (5–8) and the peptides CEF and CMV, D and Dis (manual and automated) were evaluated for Test 2, 3 and 4. The D
value is representative as accuracy measurement for the relative difference between the manual and automated spot count mean. Dis
is referring as a spot distribution statement. Donors 5 and 6 were tested as controls for Tests 2–4 but are not shown in Table 3 due to
their properties as negative CEF and CMV donors, respectively
a Values obtained from duplicate instead of triplicate due to one outlier in the automated assay
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experiment for validating the antibody compensation
(Test 3) did not show a significant change of the D and
Dis values, the maximal D value being 13.9%
compared to 12.1% for Test 2 (Table 3). The mean
D decreased slightly between Test 2 (7.6%) and Test 3
(7,3%). The Wilcoxon signed-rank test shows that the
manual and automated assays were not being signif-
icantly different (p[ 0.05). Test 3 did not afford a
high improvement of the automated process consid-
ering the D and Dis values. Nevertheless the compen-
sation of the antibody concentration remained in the
further step to be able to compare the following results
and to ensure an equal antibody end-concentration in
the wells between the manual and automated assays.
Final proof of concept
Based on the experiences gained in Tests 1, 2 and 3
many factors have been improved altogether for the
automated process. Complementary optimizations of
the process have also been introduced for Test 4with the
reduction of dead and cache volume. Due to liquid
handling parameters such as air gap, surplus of reagent
and cell solutions were prepared. To avoid wastage, the
minimum required volume in the reservoir for cells or
reagents before aspiration has been characterized. The
supply vessel used for these experiments has an inner
diameter of about 6 mm and a safety gap (between
vessel base and lowest aspiration position) was set to
1 mm. The dead volume of the container was about
30 ll (p 9 R2 9 H = p 9 32 9 1 = 28.3 ll ? min-
imal volume due to conical form of the ves-
sel & 30 ll). During the process 20 ll were lost
through multiple pipetting actions. Hence, the cache
volumemust be around 10% of the needed volume or at
least more than 50 ll (=minimum volume in cry-
ovial ? process loss volume). This value is equivalent
to the conditioning volume used in standard multi-
pipetting devices. The conditioning volume corre-
sponds to the volume dropped back to the reservoir
vessel before pipetting and guarantees an accurate
volume dispensing.
Many parameters had to be considered to automate
the manual ELISpot assay. As resumed and shown in
Table 4 the accumulated optimization steps were
focused on pipetting accuracy, washing step condi-
tions and avoidance of carryover. Considering all
these factors, the last two steps of the assay, plate
blocking and substrate development, were automated
(Test 4) and added to the process as illustrated in
Fig. 5. The workflow represents and enumerates all
steps of the manual versus automated assay with the
corresponding processing duration, some preparation
steps still having to be done manually. As revealed in
Fig. 5, the automated assay was still about 15 min
longer than the manual assay due to the exhausting
washing steps. Nevertheless, the critical loading steps
were 2–3 times shorter.
For the final proof-of-concept, we compared the
automated ELISpot assay including following steps:
blocking, cell and reagent loading (compensated)
antibody loading, washing steps and substrate devel-
opment. The optimized automated ELISpot assay was
evaluated using the same donors (5–8) than in Test 2
and 3 (Fig. 6). Two plates are exemplarily shown after
spot development: one was prepared completely
manually (Fig. 6a), the other one with the automated
ELISpot assay in parallel (Fig. 6b) with the plate
Table 4 List of encountered problems during the establishment of the ELISpot assay on our automated system and the measures
taken to improve the process to the level of the manual assay or beyond
Occurred problems New parameters Optimization
Dripping tips High blow out speed (400 ll/s) 4
Carrying over due to air bubbles at the wells’ top Z-dispense set to about 5 mm above well 4
Volume elevation after washing steps Increased removed volume (230 ll instead of 200 ll) 4
Remaining volume in wells Aspiration of liquid on edge of well 4
Long-term damage of cytokine-binding membrane
during washing steps
PBS aspirate and dispense speeds reduced to 100 ll/s and
200 ll/s, respectively
4
Residual liquid at tip end EtOH wash before and after use 4
Dead volume in 96 well plate Increased reagents and antibody concentration for the equal
pipetted volume (50 ll)
4
High reagent consumption Cache reduced to 10% (at least 50 ll) 4
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remaining in the system during the complete process.
For a more representative view of the comparison, a
histogram has been produced to illustrate the results.
Figure 7 shows the amounts of spot forming cells
(SFC) per 106 PBMCs for the reagents CEF, CMV and
PHA of the four donors (5–8) in the manual and in the
automated assay. The results of Test 4 show a D range
of 0.7–6.1% (Table 3, Test 4). This is a decrease of the
maximal D value of over 50% compared to Test 3
(13.9%) and of over 88% compared to Test 1 (54.5%).
Dismanual has a higher maximal value with 12.2 than
Disautomated with 11.1. Disautomated mean is also smaller
than the manual one. The well to well analysis with the
Wilcoxon signed-rank test results in a non-significant
difference between the manual and the automated
assays (p[ 0.05).
Fig. 5 Timeline of the manual (a) and the new established fully
automated (b) ELISpot assay. The preparation of cells, reagents,
antibodies and substrate as well as the plate post processing
(dark gray) still occurs manually and parallelized to the
automated protocol. The bright gray parts show the washing
steps that take longer for the automated assay compared to the
black parts illustrating the loading actions, which are faster. The
white boxes indicate the incubations and the scale represents
20 min process time. In the joined table, real times of each assay
operation (steps 1–15) are enumerated for both modes
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Finally, the automated ELISpot assay reached,
through process improvements described here, an
acceptable D mean of maximum 6% with a Dis mean
smaller than in the manual assay. In contrast to CEF
and CMV (with negative donors), PHA values were
analyzed for all four donors (5–8). During the
implementation phase, same donors were used for
Test 2, 3 and 4 allowing an intra-assay comparison of
the manual plates. Manual delta difference of Test 2
against Test 3, Test 2 against Test 4 and Test 3 against
Test 4 were calculated per donor. The mean of the
three correlations or comparative values was taken
resulting in an average of 26.2% showing the high
intra-assay variability of the manual procedure. This
value was important and has been used as reference
value in order to rank the inter-assay values of the
comparison between the manual and the automated
process. An intra-assay comparison of the automated
plates was not possible due to step by step improve-
ment of the automated assay conditions between Test
2, 3 and 4.
In the case of the inter-assay consistency, a big
enhancement was observed in the comparison of the D
between manual and automated plates over the
implementation process for the PHA values. For Test
1, the mean of the D value was 25.3%, for Test 2
22.0%, for Test 3 15.8% and for Test 4 7.4%. The
results are listed in Table 5 and show a three times
smaller inter-assay inconsistency between the manual
and the automated processes of the improved test (Test
4, 7.4%) than the manual mean intra-assay inconsis-
tency (26.2%).
Discussion
The ELISpot assay is one of the most important
techniques for immunomonitoring purposes and vac-
cine development. As a central method involved in
international HIV research projects and clinical trials,
the assay has to be conducted at a high level of
standardization and reproducibility worldwide to
Fig. 6 Comparison of manual (a) and automated (b) ELISpot
plates tested with four donors (Lines A–D, donors 5–8).
Columns 1–3 show the secreting cells stimulated by CEF,
columns 4–6 the ones stimulated by CMV, columns 7–9 by PHA
and columns 10–12 by medium. The amount of counted spot
forming cells (SFC) represents the immunoreaction of each
donor. The scans were operated and evaluated on an automated
CTL ImmunoSpot plate reader
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guarantee comparability of results (Janetzki et al.
2005). The most significant challenges are its inter-
operator as well as inter- and intra-assay inconsis-
tency. To address this problem, we developed an
automated ELISpot assay based on a liquid handling
pipetting platform, minimizing variability errors
caused by human and unstandardized factors. We
focused our investigation on (1) adapting the manual
procedure, (2) optimizing liquid classes for plate
loading, (3) minimizing dead volumes and (4) adapt-
ing reagent consumption and concentrations.
We were able demonstrate an implementation of
the manual ELISpot process on the automated plat-
form with comparable ELISpot counts and more
homogenous results than in the manual assay.
The results presented here are a first proof of
principle of an automated ELISpot procedure. Aside
of the technical issues of the process automation,
different challenges have been solved to enable the
transfer of the ELISpot assay on the platform. One
issue was the reduction of the dead volume cumulated
during washing steps resulting in assay variability.
Due to the solution of the adjusted peripheral aspira-
tion even up to 14.4 ll are still left, requiring to
concentrate the antibody. A complementary limitation
was the significantly increased time needed for the
automated washing steps in comparison to the manual
procedure. Indeed, the manual process includes plate
flicking that could not be transferred completely to the
automated system described here. However, in all
highly critical actions, the automated process was at
least two to three times faster than the manual process
(e.g. automated plate loading could be reduced to
3 min in contrast to 10 min for the manual loading).
For future improvement of the process, an automated
washer or a 96 liquid handling head instead of the
LiHa could be implemented in the routine to acceler-
ate the washing step. This head is based on a complex
multichannel system able to operate a plate in total so
that multiple pipetting steps become redundant.
Additionally, the velocity of plate loading and wash-
ing will increase significantly as the process of
aspirating and dispensing a 10 ll volume in each well
of a 96-well plate will only last 25 s (as specified by
the manufacturer), resulting in more homogeneously
and continuously processed plates per 24 h.
Technical limitations aside, biological effects have
also been controlled. To check the automated process
on cross-contamination and selectivity, negative CEF/
Fig. 7 Comparison of the spot forming cells (SFC) amount per
106 added PBMCs for four donors in manual (bright gray) and
automated (dark gray) ELISpot assay. The histogram illustrates
the results of Test 4, comparing the manual and the automated
spot counts. a represents the cells reaction with CEF reagent,
b the reaction in presence of CMV and c shows the positive
control with PHA. Donor 5 is CEF negative and CMV low-
responder and Donor 6 CMV negative and CEF low-responder.
Both donors are used as carryover and selectivity controls.
Donor 7 and 8 are considered as high and middle responders
with reactivity between 2000 and 7000 SFCs/106 PBMCs
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low-responder CMV and negative CMV/low-respon-
der CEF donors (donors 5 and 6) were used in Test 2.
The same donors were implemented consistently in
Test 3 and Test 4 due to comparability. No carryover
was observed throughout all experiments.
Here we prove for the first time that the automation
of main ELISpot assay steps in a robotic platform is
possible and comparable to the manual standard
protocol. Advantages of this automated assay are
standardization, improved safety, reproducibility,
quality control, and scalability as has previously been
suggested by others (Franscini et al. 2011). In
automated routines plates can be processed without
human assistance. It is possible to schedule plate
processing using a nested process structure resulting in
an optimal workflow timing, working day and night.
An automated system, being more accurate and
reproducible than an operator, will reduce the intra-
and inter-assay variability to its minimum, for exam-
ple regarding the continuously control of incubation
time (Allinson 2011). Compared to a technician
processing four to six plates within one working day,
the automated device can handle up to twelve plates in
the same time with the technician focusing on other
work in parallel. Altogether the turnaround time with
an automated ELISpot assay is about four to six times
higher than manual performed ELISpots. Our results
directly address the growing need for (integrated)
automation in cell processing and storage as robotic
systems can improve accuracy and precision as well as
time- and cost-efficiency (Bodin 1995; Cox et al.
2004; Dimech 2000).
The robot platform is highly flexible and pro-
grammable for different purposes. It has already been
configured and applied for e.g. stem cell
differentiation (Meiser et al. 2013) and for the
cultivation and maintenance of different cell lines,
like pluripotent stem cells. To extend the platform, a
centrifuge, a reagent cooling system as well as an
optional coupled cryopreservation station could be
added in the future, enabling the complete assay to be
run automatically from PBMC isolation over cryop-
reservation, cell and reagent preparation to plate
development. This complex scenario matches the
vision of Janetzki et al. (2004) a decade ago and since
required hardware is now available it could be
developed in the near future. Devices for automated
blood isolation (PBM200, AM Robotic Systems,
Warrington, United Kingdom) and semi- and fully
automatic freezing and thawing supplies are now
commercially available (Immunocite Technologies,
Miramar, FL, USA, and Me´Cour, Groveland, MA,
USA) according to the standards of the Society for
Laboratory Automation and Screening (SLAS).
Besides, automatable cell preparation tubes (Vacu-
tainer CPT, BD, Heidelberg, Germany) are used as
improved alternative to Ficoll gradient (Ruitenberg
et al. 2006) for PBMC separation. The platform could
be used after validation as a ready-to-use and fully
automated cell and liquid handling system with the
integration of a 96 multichannel head, the cell
separation system including a centrifuge, and the
adaptation of a cryo storage supply. This systemwould
have the ability to produce high-throughput, safe and
GLP-conform ELISpot assays that are required in
clinical trials (Slota et al. 2011) as well as in
laboratories with high biosafety levels in which
research for instance on tuberculosis (Kobashi et al.
2010), malaria (Gonzalez et al. 2000) or Bulgarian
Crimean–Congo hemorrhagic fever (Mousavi-Jazi
Table 5 Statistics of the inter- and intra-assay inconsistency for Test 1 to Test 4 and donor 1 to donor 8 for the PHA reagent
Comparison D Mean (%) Mean
Intra-assay consistency (manual) Test 2 against Test 3 31.9 26.2
Test 2 against Test 4 38.1
Test 3 against Test 4 8.7
Inter-assay consistency (manual against automated) Test 1 25.3 –
Test 2 22.0 –
Test 3 15.8 –
Test 4 7.4 –
The mean delta value represents the mean of the D between the manual and automated spot count mean for the four donors
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et al. 2012) demand secured tests. With the technical
potential and the capacity for adaptations, the robot
platform could not only be used for stem cell research
and immunological assays such as neutralization tests
for HIV vaccine search (Schultz et al. 2012) but also
for multiple further applications where accuracy,
precision, reproducibility, scalability and operator
safety are crucial.
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